Loading…
← CockpitCompetitor Analysis › VCEL Vericel CorporationOpen in the cockpit ↗

Vericel CorporationVCELCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Makes cell-based therapies for knee cartilage repair (MACI) and severe burn treatment (Epicel, NexoBrid).

Momentum leader 98
Mkt cap
$2.99B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$49.5M
20-day average traded
Fwd P/E
68.3×
forward earnings
ROIC−WACC
-3.4 pp
WACC 10.3%
Hurdle
+29 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$58.65
1D+1.3%
1W-1.4%
1M+44.5%
3M+39.3%
6M+65.7%
YTD+62.9%
1Y+48.7%
ATR %4.0%
Beta0.50
52w lowhigh1.8% off high

What Vericel does

Makes cell-based therapies for knee cartilage repair (MACI) and severe burn treatment (Epicel, NexoBrid).

MACI is made per patient: surgeons send a cartilage sample, Vericel grows the person's own cells and ships them back for a second operation, and insurers pay for each case, so procedure counts drive results. Epicel is made the same way for burns; NexoBrid is licensed in from MediWound for US sales.

Products and services

  • MACI (cartilage repair)
  • Epicel (severe burns)
  • NexoBrid (burn debridement)

Customers

  • Orthopedic surgeons
  • Burn centers

Where it sits in the supply chain

  • Cell/regenerative therapy
  • Autologous cartilage-cell manufacturing
  • Specialty surgical/burn-center sales

What could go right

  • MACI case-volume growth
  • NexoBrid adoption in US burn centers

What could go wrong

  • Niche/small addressable markets
  • Manufacturing capacity constraints for cell therapies

Moat: narrow (regulatory licence, process know-how, installed base). Complex cell-manufacturing and scarce burn-center relationships are difficult for new entrants to replicate.

Headquarters: Cambridge, Massachusetts, US · Founded: 2014 · Employees: 398

Named competitors

Vericel at a glance

Size Vericel (VCEL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.99B, the 1544th largest of 3,085 United States companies the cockpit tracks. Shares closed at $58.65 on 18 Nov 2026.

Performance Over six months the shares gained 65.7%, against -6.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 25.3% over the last twelve months (peer median +14.8%); the operating margin is 8.3% (peer median 14.8%).

Valuation It trades at 68.3× forward earnings against a peer median of 22.1× (2nd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 46% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.4 points below its cost of capital (10.3% WACC).

Short interest Short interest is 10.5% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026VCEL 167Peer median 96
Six months, rebased to 100: Vericel against the median of its 20 peers (local-currency closes).

Vericel financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$324M$276M$237M$198M$164M
Revenue growth—+16%+20%+20%—
Gross profit$241M$206M$172M$136M$110M
EBITDA$40.6M$22.6M$10.0M-$1.83M-$8.86M
Net income$33.3M$16.5M$10.4M-$3.18M-$16.7M
Free cash flow$57.9M$24.7M-$5.81M$15.3M$9.02M
Capital expenditure$7.42M$27.2M$64.0M$27.5M$7.60M
Total debt$92.6M$98.3M$99.8M$88.1M$47.6M

Quarterly statements and history in the cockpit →

Vericel competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%+40%0027730867NEULANDLAB2696ACADLEGN688266600380600535300558VKTX300199000739PPLPHARMA2096VRDNAMLX600518VCEL6-month return →1-month return →
Up and to the right = strong over both horizons. Vericel is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%0×50×100×150×0027730867NEULANDLAB2696LEGN688266600380300558300199000739BIOA-BPPLPHARMA2096VCELRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Vericel is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%00277308672696ACAD688266600380600535600511300558300199000739BIOA-BVCELGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Vericel is the large dot.

Vericel competitors and peer comparison

Head to head with its named competitors (VCEL vs ORGO vs SN..L vs IART)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Vericel VCEL$2.99B+66%+25%8%68.3×46.5%
Organogenesis ORGOn/a-67%n/an/an/an/a
Smith & Nephew SN..L$12.6B+1%+2%17%14.2×11.1%
Integra LifeSciences IART$1.08B-10%+1%12%6.0×5.9%
AVITA Medical RCEL$529M+290%+17%-34%n/an/a

How Vericel compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vericel against its 20 peers (data as of 18 Nov 2026)
MeasureVCELPeer medianRank in peer set
1-month return+44.5%-1.4%highest of 21
6-month return+65.7%-6.6%3rd highest of 21
Distance from 52-week high-1.8%-29.6%highest of 21
Revenue growth (TTM)+25.3%+14.8%8th highest of 20
Operating margin8.3%14.8%6th lowest of 19
Forward P/E68.3×22.1×2nd most expensive of 17
Growth the price implies (Req g, 7 yrs)46.5%4.7%most demanding of 14
Growth delivered (Del g)+17.3%+7.0%5th highest of 14
Hurdle (Req g minus delivered)+29.2 pp-10.2 pp2nd most demanding of 14
ROIC minus cost of capital-3.4 pp+4.2 pp4th lowest of 16
EV / EBITDA71.7×18.7×most expensive of 8
Net debt / EBITDA-1.9×-0.8×4th least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a

Questions

Who are Vericel's main competitors?
Named competitors: Organogenesis (ORGO), Smith+Nephew (SN..L), Integra LifeSciences (IART), Avita Medical (RCEL), Anika Therapeutics (private or unlisted). The cockpit's measured peer set (industry) also includes Chengdu Kanghong Pharmaceutical (002773.SZ), China Medical System (0867.HK), Neuland Laboratories (NEULANDLAB.NS), Shanghai Henlius Biotech (2696.HK), ACADIA Pharmaceuticals (ACAD), Legend Biotech Corp. Sponsored ADR (LEGN).
Is Vericel expensive compared with its peers?
On forward p/e it trades at 68.3× against a peer median of 22.1×, 2nd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 46% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Vericel stock performed?
Over six months to 18 Nov 2026 the shares returned +65.7% against -6.6% for the median peer; over one year +48.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.